Ventyx Biosciences Email Format
Biotechnology ResearchCalifornia, United States201-500 Employees
Ventyx Biosciences is a clinical-stage biotechnology company focused on developing oral therapies for autoimmune, inflammatory, and neurodegenerative diseases. It leverages expertise in medicinal chemistry, structural biology, and immunology to discover small-molecule drugs and advance them through clinical development. The lead program portfolio includes NLRP3 inhibitors such as VTX2735, a peripherally restricted compound, and VTX3232, a CNS-penetrant inhibitor, along with inflammatory bowel disease candidates tamuzimod (VTX002) and VTX958, both having completed Phase 2 trials. The company is based in San Diego, California, and operates as a mid-sized biopharmaceutical firm. Recent activity includes presentations of VTX3232 Phase IIa results at the ACC 75th Annual Scientific Session in March 2026, highlighting ongoing clinical progress.